Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Among authors: dereure o. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network.
Zagala R, Dalle S, Beylot-Barry M, Meyer N, Saiag P, Kramkimel N, Lebbe C, Zehou O, Amini-Adle M, Grob JJ, Arnault JP, Maubec E, Granel-Brocard F, Cribier B, Quereux G, Brunet-Possenti F, Dalac S, Dereure O, Drumez E, Mortier L, Battistella M, Jouary T. Zagala R, et al. Among authors: dereure o. J Eur Acad Dermatol Venereol. 2024 Jun 12. doi: 10.1111/jdv.20155. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38864258
French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis).
Ingen-Housz-Oro S, Matei I, Gaillet A, Gueudry J, Zaghbib K, Assier H, Hua C, Bensaid B, Colin A, Ouedraogo R, Redlich J, Courtois E, Chazelas K, Sbidian E, Nakad L, Bequignon E, Terkmane N, Gaultier F, Schlemmer F, Do-Pham G, Barbaud A, Lebrun-Vignes B, Hoffmann C, Mahé PJ, Le Floch R, Bernier C, Vabres B, Milpied B, Delcampe A, Tétart F, Tauber M, Staumont-Sallé D, Dezoteux F, Descamps V, Misery L, Bursztejn AC, Dereure O, Amazan E, Le Bidre E, Le Pallec S, Lagier C, Laroche A, Ferrat E, Wolkenstein P, de Prost N; French National Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL. Ingen-Housz-Oro S, et al. Among authors: dereure o. Ann Dermatol Venereol. 2024 May 28;151(2):103282. doi: 10.1016/j.annder.2024.103282. Online ahead of print. Ann Dermatol Venereol. 2024. PMID: 38810539 Free article. No abstract available.
Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study).
Tzoumpa S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, El Aarbaoui T, Dereure O, Quereux G, Faiz S, de Vicq de Cumptich M, Ram-Wolff C, Janela-Lapert R, Guenova E, Lheure C, Le Corre Y, Adamski H, Blanchard M, Bonnet N, Amatore F, Grange F, Troin L, Bagot M, Beylot-Barry M. Tzoumpa S, et al. Among authors: dereure o. Br J Dermatol. 2024 Apr 25:ljae153. doi: 10.1093/bjd/ljae153. Online ahead of print. Br J Dermatol. 2024. PMID: 38660811 No abstract available.
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M, Lamoureux A, Meunier L, Samaran Q, Lesage C, Girard C, Du Thanh A, Moulis L, Dereure O. Fabre M, et al. Among authors: dereure o. Melanoma Res. 2024 Jun 1;34(3):241-247. doi: 10.1097/CMR.0000000000000963. Epub 2024 Mar 28. Melanoma Res. 2024. PMID: 38546723
510 results